Bertilimumab 产品活性：Bertilimumab (CAT 213; iCo-008) 是一种靶向 eotaxin-1 (CCL11) 的人单克隆抗体。Bertilimumab 具有用于过敏性疾病研究的潜力。 产品来源： https://www.medchemexpress.cn/bertilimumab.html 研究领域：GPCR/G Protein | Immunology/Inflammation 作用靶点：CCR In Vitro: Bertilimumab (CAT 213) neutralizes the ability of eotaxin-1 to cause an increase in intracellular calcium signaling (with an IC50 value of 2.86 nM), migration of CCR3-expressing L1.2 cells (with an IC50 value of 0.48 nM), and inhibition of the eotaxin1-evoked shape change of human eosinophils in vitro (with an IC50 of 0.71 nM). In Vivo: Bertilimumab (CAT 213) (0.01-10 mg/kg) administered i.v. 30 min before i.po. injection of human eotaxin1 (1 μg) causes a significant dose-dependent inhibition of eosinophil recruitment in IL-5-treated, ovalbumin-sensitized mice. Bertilimumab also significantly inhibits neutrophil and mononuclear cell influx into the air pouch, which resulted in a dose-related inhibition of total cell influx. 相关产品：Pirfenidone | Maraviroc | RS 504393 | Bindarit | BX471 | INCB3344 | RS102895 hydrochloride | Cenicriviroc | PF-4136309 | TAK-779 | Zelnecirnon | CCR6 antagonist 1 | CCR6 inhibitor 1 | AZ084 | ZK756326 dihydrochloride | AZD2098 | C-021 | GW 766994 | R243 | Tivumecirnon | 7,4'-Dihydroxyflavone | CCR2 antagonist 4 hydrochloride | K777 | Vercirnon | BMS-813160 | CCR7 Ligand 1 | J-113863 | MK-0812 Succinate 品牌介绍: MCE (MedChemExpress) 拥有数百种全球独家化合物，我们致力于为全球科研客户提供最新最全的高品质小分子活性化合物；10,000 多种高选择性抑制剂、激动剂涉及各热门信号通路及疾病领域；设有专业的实验中心和严格的质控、验证体系；提供 LC/MS、NMR、HPLC、手性分析、元素分析等各项质检报告，确保产品的高纯度、高品质；产品的生物活性多经各国客户实验验证；Nature, Cell, Science 等多种顶级期刊及制药专利收录了MCE客户的科研成果；专业团队跟踪最新的制药及生命科学研究进展，为您提供全球最新的活性化合物；与世界各大制药公司及知名科研机构建立了长期的合作。